Bausch Health Companies Inc. Disposal Group, Including Discontinued Operation, Assets, Current
Bausch Health Companies Inc. (BHC) had Disposal Group, Including Discontinued Operation, Assets, Current of $0 as of 2017-12-31, per its 8-K filed 2018-08-10.
Discontinued › Balance Sheet › Assets › Assets, Current › Disposal Group, Including Discontinued Operation, Assets, Current
us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent · last filed 2018-08-10
- 2017-12-31: Disposal Group, Including Discontinued Operation, Assets, Current $0.00.
- 2017-09-30: Disposal Group, Including Discontinued Operation, Assets, Current $16.00M.
- 2017-06-30: Disposal Group, Including Discontinued Operation, Assets, Current $77.00M.
- 2017-03-31: Disposal Group, Including Discontinued Operation, Assets, Current $240.00M.
| Period end | Disposal Group, Including Discontinued Operation, Assets, Current |
|---|---|
| 2017-12-31 | $0.00 8-K · filed 2018-08-10 |
| 2017-09-30 | $16.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $77.00M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $240.00M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $261.00M 8-K · filed 2018-08-10 |
| 2015-12-31 | $3.00M 10-K · filed 2017-03-01 |
| 2015-03-31 | $7.80M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $8.90M 10-Q · filed 2015-04-30 |
| 2013-12-31 | $15.90M 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |